Syngene International

Bengaluru, India
Find alternatives to Syngene International for Biologics →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
80.3
Signal Score
✓ FDA Inspections (3) ○ Clinical Trials ○ SEC Filings ✓ Press (12) ○ EMA GMP ○ MHRA GMP ✓ HC GMP (16)

Quick Facts: Syngene International

Signal Score
80.3/100 (as of 2026-10-29)
Quality Compliance
100.0/100 — Bonus: 3 consecutive NAI inspections
Headquarters
Bengaluru, India
Modalities
Biologics, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed — 1 partnership signal in press (announcements, not verified)
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Syngene International

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Bonus: 3 consecutive NAI inspections
Sources: FDA Data Dashboard
Bonus: 3 consecutive NAI inspections
FDA Inspections3 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-02-20)
Most Recent HC OutcomeCompliant · 2025-02-10
HC Attribution16 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Bonus: 3 consecutive NAI inspections
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesBiologics, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: Biocon
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Biocon
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Bangalore, IN
Modalities: Biologics, Cell Therapy
Capacity assessment: 58.0/100
Sites: Bangalore, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals12 articles (not scored)
1 manufacturing site: Bangalore, IN
Modalities: Biologics, Cell Therapy
Capacity assessment: 58.0/100

Syngene International FDA Inspection History

2025-02
2023-05
2022-10
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-02-20
Syngene International Ltd.
Bengaluru Facility-linked
Drug Quality Assurance Not posted No Action Indicated (NAI)
2023-05-26
Syngene International Limited
Dakshina Kannada, Mangalore Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2022-10-28
Syngene International Limited
Bengalore Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

general (non-sterile) · 1 site

  • Bengaluru, India · Syngene International Limited — general (non-sterile) · valid to May 18, 2027 renewal due

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity 4 open roles Beta

From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
4
open roles
3
in manufacturing, quality, PD/MSAT, engineering or regulatory (75%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 60 taken down.
By function
Process development & MSAT 1
Engineering & facilities 2
Commercial, BD & client projects 1
By site
Baltimore
· 1 PD/MSAT · 2 eng. · 1 other
4
Modality words in job titles
Biologics (cell culture, USP/DSP)1
Notable roles
Director Engineering and Maintenance Senior operations / quality role · Baltimore
Latest postings
Senior Process Engineer Process development & MSAT · Baltimore
Manager Facilities Engineering & facilities · Baltimore
Director Engineering and Maintenance Engineering & facilities · Baltimore
Director Business Development Biologics, East Coast U.S. Commercial, BD & client projects · Baltimore
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Baltimore biologics manufacturing site only. The Bangalore campus mixes research services and manufacturing, so it is left out and this count is low). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: careers.syngeneintl.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 12 articles

Company announcements, not verified evidence. They do not change any score.
regulatory 2026-10-28
Syngene International (NSE:SYNGENE) Q2 FY27 Results and Business Update - Kalkine India
Syngene International (NSE:SYNGENE) Q2 FY27 Results and Business Update  Kalkine India
general 2026-10-27
Syngene International posts Rs 32.2-crore profit in Q2, rebounds from Q1 loss - ABP Live English
Syngene International posts Rs 32.2-crore profit in Q2, rebounds from Q1 loss  ABP Live English
financial 2026-10-27
Syngene International: Q2 FY27 Revenue Up 13% Sequentially, EBITDA Margin Improves - InvestyWise
Syngene International: Q2 FY27 Revenue Up 13% Sequentially, EBITDA Margin Improves  InvestyWise
regulatory 2026-04-30
Syngene International Reports Modest 3% FY26 Revenue Growth Amid Biologics Headwinds - IndiaMedToday
Syngene International Reports Modest 3% FY26 Revenue Growth Amid Biologics Headwinds  IndiaMedToday
general 2026-04-29
Syngene International Q4 net down 19 pc at Rs 147.9 cr - Devdiscourse
Syngene International Q4 net down 19 pc at Rs 147.9 cr  Devdiscourse
general 2026-04-18
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for  AD HOC NEWS
general 2026-04-18
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for  AD HOC NEWS
general 2026-04-11
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for  AD HOC NEWS
regulatory 2026-03-20
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 - AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26  AD HOC NEWS
regulatory 2026-03-20
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 - AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26  AD HOC NEWS
general 2026-03-15
Syngene International Stock (ISIN: INE398A01010) Faces Pressure Amid Biopharma Contract Slowdown - ad-hoc-news.de
Syngene International Stock (ISIN: INE398A01010) Faces Pressure Amid Biopharma Contract Slowdown  AD HOC NEWS
partnership 2026-02-19
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure - BioSpace
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure  BioSpace

Frequently Asked Questions About Syngene International

How many FDA inspections does Syngene International have on record?
CDMO Signal tracks 3 FDA inspections for Syngene International, sourced from the FDA inspection database. See the full inspection history above.
Has Syngene International received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Syngene International.
What is Syngene International's CDMO Signal Score?
Syngene International has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating Syngene International for a manufacturing program?
Use the free AI matchmaker to compare Syngene International against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.9
mRNA, Biologics, Cell Therapy
Eurofins CDMO
Planegg, DE · San Diego, CA
Signal Score: 81.6
Biologics, Cell Therapy
ProBio
Pennington, NJ · Nanjing, CN
Signal Score: 64.0
mRNA, Biologics, CAR-T, Cell Therapy
Singota Solutions
Bloomington, IN
Signal Score: 59.0
Cell Therapy, Biologics
Biocon Biologics
Bengaluru, India
Signal Score: 75.7
Cell Therapy

Compare Syngene International with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Syngene International
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.